These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25583156)

  • 1. Epoxyeicosatrienoic acids, hypertension, and kidney injury.
    Imig JD
    Hypertension; 2015 Mar; 65(3):476-82. PubMed ID: 25583156
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.
    Certíková Chábová V; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Kujal P; Vernerová Z; Vanourková Z; Kopkan L; Kramer HJ; Falck JR; Imig JD; Hammock BD; Vanecková I; Cervenka L
    Clin Sci (Lond); 2010 Feb; 118(10):617-32. PubMed ID: 20050826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epoxyeicosatrienoic acids--novel mechanism and pharmacological therapy of chronic renocardiac syndrome.
    Huang H; Chen J; Lin T; Wang T; Tang Y; Dong Y; Wang J
    Med Hypotheses; 2011 Apr; 76(4):550-2. PubMed ID: 21333454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?
    Weir MR
    Curr Hypertens Rep; 2000 Dec; 2(6):497-9. PubMed ID: 11062593
    [No Abstract]   [Full Text] [Related]  

  • 5. Orally Active Epoxyeicosatrienoic Acid Analogs.
    Campbell WB; Imig JD; Schmitz JM; Falck JR
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):211-224. PubMed ID: 28937442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented.
    Bakris GL; Ritz E;
    Clin Exp Nephrol; 2009 Feb; 13(1):96-9. PubMed ID: 19184272
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage.
    Mennuni S; Rubattu S; Pierelli G; Tocci G; Fofi C; Volpe M
    J Hum Hypertens; 2014 Feb; 28(2):74-9. PubMed ID: 23803592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.
    Imig JD; Jankiewicz WK; Khan AH
    Hypertension; 2020 Jul; 76(1):3-15. PubMed ID: 32475311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats.
    Alp Yildirim FI; Eker Kizilay D; Ergin B; Balci Ekmekçi Ö; Topal G; Kucur M; Demirci Tansel C; Uydeş Doğan BS
    Eur J Pharmacol; 2015 Oct; 764():433-442. PubMed ID: 26187312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators.
    Campbell WB
    Trends Pharmacol Sci; 2000 Apr; 21(4):125-7. PubMed ID: 10740283
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypertension in renal parenchymal disease: why is it so resistant to treatment?
    Campese VM; Mitra N; Sandee D
    Kidney Int; 2006 Mar; 69(6):967-73. PubMed ID: 16528245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive therapy and progression of chronic renal disease.
    Dworkin LD; Shemin DG
    Curr Hypertens Rep; 1999 Oct; 1(5):417-22. PubMed ID: 10981100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic hypertension and antihypertensive agents.
    Maschio G; Marcantoni C; Bernich P
    J Nephrol; 1999; 12 Suppl 2():S100-4. PubMed ID: 10688408
    [No Abstract]   [Full Text] [Related]  

  • 14. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
    Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
    Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of blood pressure reduction for prevention of progression of renal disease.
    Textor SC; Canzanello VJ
    Curr Hypertens Rep; 1999 Oct; 1(5):423-30. PubMed ID: 10981101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasodilatory responses of renal interlobular arteries to epoxyeicosatrienoic acids analog are not enhanced in Ren-2 transgenic hypertensive rats: evidence against a role of direct vascular effects of epoxyeicosatrienoic acids in progression of experimental heart failure.
    Sporková A; Husková Z; Škaroupková P; Rami Reddy N; Falck JR; Sadowski J; Červenka L
    Physiol Res; 2017 Mar; 66(1):29-39. PubMed ID: 27782740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertension and the kidney].
    Hohenstein K; Watschinger B
    Wien Med Wochenschr; 2008; 158(13-14):359-64. PubMed ID: 18677585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoxyeicosanoids in hypertension.
    Imig JD
    Physiol Res; 2019 Oct; 68(5):695-704. PubMed ID: 31475560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of antihypertensive treatment on target organs].
    Fregoso Padilla J
    Arch Cardiol Mex; 2002; 72 Suppl 1():S58-63. PubMed ID: 12001872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.